News | January 29, 2021
Laurus Q3 FY21 revenue up 76%; PAT grows 274%
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
The company is expecting tremendous growth and a better quarterly performance
Subscribe To Our Newsletter & Stay Updated
